CD44 family proteins in gastric cancer: A meta-analysis and narrative review

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 3, 2015, Pages 3595-3606

  Wu, Ying ^a   Li, Zhi ^a   Zhang, Chenlu ^a   Yu, Kai ^a   Teng, Zan ^a   Zheng, Guoliang ^b   Wang, Shuang ^a   Liu, Yunpeng ^a   Cui, Lei ^a   Yu, Xiaosong ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b LIAONING CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

CD44 variants; CD44s; Gastric cancer; Meta analysis; Narrative review; Prognosis

Indexed keywords

HERMES ANTIGEN;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DISTANT METASTASIS; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS; OVERALL SURVIVAL; STOMACH CANCER; TUMOR DIFFERENTIATION;

EID: 84929379428     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Parkin DM, Bray F, Ferlay J and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Resende C, Thiel A, Machado JC and Ristimaki A. Gastric cancer: basic aspects. Helicobacter 2011; 16 Suppl 1: 38-44.
3. Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M and Nakayama H. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 2005; 8: 86-94.
4. Chen S, Hou JH, Feng XY, Zhang XS, Zhou ZW, Yun JP, Chen YB and Cai MY. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma. J Surg Oncol 2013; 107: 799-806.
5. Ryu HS, Park do J, Kim HH, Kim WH and Lee HS. Combination of epithelial-mesenchymal transition and cancer stem cell-like phenotypes has independent prognostic value in gastric cancer. Hum Pathol 2012; 43: 520-528.
6. Wang T, Ong CW, Shi J, Srivastava S, Yan B, Cheng CL, Yong WP, Chan SL, Yeoh KG, Iacopetta B and Salto-Tellez M. Sequential expression of putative stem cell markers in gastric carcinogenesis. Br J Cancer 2011; 105: 658-665.
7. Klonisch T, Wiechec E, Hombach-Klonisch S, Ande SR, Wesselborg S, Schulze-Osthoff K and Los M. Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol Med 2008; 14: 450-460.
8. Ishigami S, Ueno S, Arigami T, Uchikado Y, Setoyama T, Arima H, Kita Y, Kurahara H, Okumura H, Matsumoto M, Kijima Y and Natsugoe S. Prognostic impact of CD133 expression in gastric carcinoma. Anticancer Res 2010; 30: 2453-2457.
9. Wakamatsu Y, Sakamoto N, Oo HZ, Naito Y, Uraoka N, Anami K, Sentani K, Oue N and Yasui W. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathol Int 2012; 62: 112-119.
10. Dhingra S, Feng W, Brown RE, Zhou Z, Khoury T, Zhang R and Tan D. Clinicopathologic significance of putative stem cell markers, CD44 and nestin, in gastric adenocarcinoma. Int J Clin Exp Pathol 2011; 4: 733-741.
11. Li K, Dan Z and Nie YQ. Gastric cancer stem cells in gastric carcinogenesis, progression, prevention and treatment. World J Gastroenterol 2014; 20: 5420-5426.
12. Doventas A, Bilici A, Demirell F, Ersoy G, Turna H and Doventas Y. Prognostic significance of CD44 and c-erb-B2 protein overexpression in patients with gastric cancer. Hepa-togastroenterology 2012; 59: 2196-2201.
13. Hsieh HF, Yu JC, Ho LI, Chiu SC and Harn HJ. Molecular studies into the role of CD44 variants in metastasis in gastric cancer. Mol Pathol 1999; 52: 25-28.
14. Jang BI, Li Y, Graham DY and Cen P. The Role of CD44 in the Pathogenesis, Diagnosis, and Therapy of Gastric Cancer. Gut Liver 2011; 5: 397-405.
15. Nagano O and Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci 2004; 95: 930-935.
16. Shi J, Yao D, Liu W, Wang N, Lv H, He N, Shi B, Hou P and Ji M. Frequent gene amplification predicts poor prognosis in gastric cancer. Int J Mol Sci 2012; 13: 4714-4726.
17. Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, Gordon SA, Shimada Y and Wang TC. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009; 27: 1006-1020.
18. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, Masuko T, Shimizu T, Ishikawa T, Kai K, Takahashi E, Imamura Y, Baba Y, Ohmura M, Suematsu M, Baba H and Saya H. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011; 19: 387-400.
19. Yoshida GJ and Saya H. Inversed relationship between CD44 variant and c-Myc due to oxidative stress-induced canonical Wnt activation. Biochem Biophys Res Commun 2014; 443: 622-627.
20. Mayer B, Jauch KW, Gunthert U, Figdor CG, Schildberg FW, Funke I and Johnson JP. De-novo expression of CD44 and survival in gastric cancer. Lancet 1993; 342: 1019-1022.
21. Yoo CH, Noh SH, Kim H, Lee HY and Min JS. Prognostic significance of CD44 and nm23 expression in patients with stage II and stage IIIA gastric carcinoma. J Surg Oncol 1999; 71: 22-28.
22. Kim JY, Bae BN, Kim KS, Shin E and Park K. Osteopontin, CD44, and NFkappaB expression in gastric adenocarcinoma. Cancer Res Treat 2009; 41: 29-35.
23. Hong RL, Lee WJ, Shun CT, Chu JS and Chen YC. Expression of CD44 and its clinical implication in diffuse-type and intestinal-type gastric adenocarcinomas. Oncology 1995; 52: 334-339.
24. Saito H, Tsujitani S, Katano K, Ikeguchi M, Maeta M and Kaibara N. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma. Cancer 1998; 83: 1094-1101.
25. Songun I, Litvinov SV, van de Velde CJ, Pals ST, Hermans J and van Krieken JH. Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. Br J Cancer 2005; 92: 1767-1772.
26. Tierney JF, Stewart LA, Ghersi D, Burdett S and Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16.
27. Parmar MK, Torri V and Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834.
28. Muller W, Schneiders A, Heider KH, Meier S, Hommel G and Gabbert HE. Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer. J Pathol 1997; 183: 222-227.
29. Hirata K, Suzuki H, Imaeda H, Matsuzaki J, Tsugawa H, Nagano O, Asakura K, Saya H and Hibi T. CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence. Br J Cancer 2013; 109: 379-386.
30. Mirecka J, Marx D and Schauer A. Immunohistochemical localization of CD44 variants 5 and 6 in human gastric mucosa and gastric cancer. Anticancer Res 1995; 15: 1459-1465.
31. Yamaguchi A, Saito M, Gio T, Iida A, Takeuchi K, Hirose K, Nakagawara G, Urano T, Furukawa K and Shiku H. Expression of CD44 variant exons 8-10 in gastric cancer. Jpn J Cancer Res 1995; 86: 1166-1171.
32. Li H, Guo L, Li JW, Liu N, Qi R and Liu J. Expression of hyaluronan receptors CD44 and RHAMM in stomach cancers: relevance with tumor progression. Int J Oncol 2000; 17: 927-932.
33. Isozaki H, Ohyama T and Mabuchi H. Expression of cell adhesion molecule CD44 and sialyl Lewis A in gastric carcinoma and colorectal carcinoma in association with hepatic metastasis. Int J Oncol 1998; 13: 935-942.
34. Chong JM, Fukayama M, Hayashi Y, Funata N, Takizawa T, Koike M, Muraoka M, Kikuchi-Yanoshita R, Miyaki M and Mizuno S. Expression of CD44 variants in gastric carcinoma with or without Epstein-Barr virus. Int J Cancer 1997; 74: 450-454.
35. Yasui W, Kudo Y, Naka K, Fujimoto J, Ue T, Yokozaki H and Tahara E. Expression of CD44 containing variant exon 9 (CD44v9) in gastric adenomas and adenocarcinomas: relation to the proliferation and progression. Int J Oncol 1998; 12: 1253-1258.
36. Ura H, Denno R and Hirata K. Correlation between nm23 protein and several cell adhesion molecules in human gastric carcinoma. Jpn J Cancer Res 1996; 87: 512-517.
37. Chen J, Li T, Liu Q, Jiao H, Yang W, Liu X and Huo Z. Clinical and prognostic significance of HIF-1alpha, PTEN, CD44v6, and survivin for gastric cancer: a meta-analysis. PLoS One 2014; 9: e91842.
38. Setala L, Lipponen P, Tammi R, Tammi M, Eskelinen M, Alhava E and Kosma VM. Expression of CD44 and its variant isoform v3 has no prognostic value in gastric cancer. Histopathology 2001; 38: 13-20.
39. Xie JW, Huang CM, Zheng CH, Li P, Wang JB, Lin JX and Lu J. [Expression tumor stem cell surface marker CD44 in gastric cancer and its significance]. Zhonghua Wei Chang Wai Ke Za Zhi 2013; 16: 1107-1112.